Helen M. Thackray, Chief R&D Officer at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 3,125 shares at $10.89 ($34K) on 2022-12-15, disclosed to the SEC on 2022-12-19.
Scheduled sale ($34k) by Chief R&D Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BCRX | SELL | 2022-04-04 | $123K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |
| GLYC | SELL | 2017-09-18 | $26K | — | Filing → |